ARID1A loss negatively correlates with the prognosis of 0.24–1.49OCCC. A, Top, representative images of ARID1A-negative or -positive OCCC clinical specimens and their respective Frequency distribution of the immunoreactivity scores for ARID1A; the dotted line represents the cutoff used to discriminate between ARID1A positive (+) and ARID1A negative (−) patients. C, Survival curves of ARID1A⁺vs. ARID1A⁻ patients expressed in years. From the left to the right: PFS [36 vs. 19; P = 0.046; HR = 0.43; 95% confidence interval (CI), 0.19–0.98], cancer-specific survival, CSS (36 vs. 18; P = 0.003; HR = 0.18; 95% CI, 0.06–0.55), overall survival (OS; 36 vs. 19; P = 0.004; HR = 0.23, 95% CI, 0.09–0.63).